PT - JOURNAL ARTICLE AU - Cilleros-Portet, Ariadna AU - Lesseur, Corina AU - Marí, Sergi AU - Cosin-Tomas, Marta AU - Lozano, Manuel AU - Irizar, Amaia AU - Burt, Amber AU - García-Santisteban, Iraia AU - Martín, Diego Garrido AU - Escaramís, Geòrgia AU - Hernangomez-Laderas, Alba AU - Soler-Blasco, Raquel AU - Breeze, Charles E. AU - Gonzalez-Garcia, Bárbara P. AU - Santa-Marina, Loreto AU - Chen, Jia AU - Llop, Sabrina AU - Fernández, Mariana F. AU - Vrijhed, Martine AU - Ibarluzea, Jesús AU - Guxens, Mònica AU - Marsit, Carmen AU - Bustamante, Mariona AU - Bilbao, Jose Ramon AU - Fernandez-Jimenez, Nora TI - Potentially causal associations between placental DNA methylation and schizophrenia and other neuropsychiatric disorders AID - 10.1101/2023.03.07.23286905 DP - 2023 Jan 01 TA - medRxiv PG - 2023.03.07.23286905 4099 - http://medrxiv.org/content/early/2023/03/08/2023.03.07.23286905.short 4100 - http://medrxiv.org/content/early/2023/03/08/2023.03.07.23286905.full AB - Increasing evidence supports the role of placenta in neurodevelopment and potentially, in the later onset of neuropsychiatric disorders. Recently, methylation quantitative trait loci (mQTL) and interaction QTL (iQTL) maps have proven useful to understand SNP-genome wide association study (GWAS) relationships, otherwise missed by conventional expression QTLs. In this context, we propose that part of the genetic predisposition to complex neuropsychiatric disorders acts through placental DNA methylation (DNAm). We constructed the first public placental cis-mQTL database including nearly eight million mQTLs calculated in 368 fetal placenta DNA samples from the INMA project, ran cell type- and gestational age-imQTL models and combined those data with the summary statistics of the largest GWAS on 10 neuropsychiatric disorders using Summary-based Mendelian Randomization (SMR) and colocalization. Finally, we evaluated the influence of the DNAm sites identified on placental gene expression in the RICHS cohort. We found that placental cis-mQTLs are highly enriched in placenta-specific active chromatin regions, and useful to map the etiology of neuropsychiatric disorders at prenatal stages. Specifically, part of the genetic burden for schizophrenia, bipolar disorder and major depressive disorder confers risk through placental DNAm. The potential causality of several of the observed associations is reinforced by secondary association signals identified in conditional analyses, regional pleiotropic methylation signals associated to the same disorder, and cell type- imQTLs, additionally associated to the expression levels of relevant immune genes in placenta. In conclusion, the genetic risk of several neuropsychiatric disorders could operate, at least in part, through DNAm and associated gene expression in placenta.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://github.com/ariadnacilleros/Cis-mQTL-mapping-protocol-for-methylome https://github.com/ariadnacilleros/Cilleros-PortetA.etal Funding StatementN.F.J. is funded by research grants 2019/111085 from the Basque Department of Health, and PI21/01491 from the Instituto de Salud Carlos III (ISCIII), co-funded by the European Union.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript or online at: https://smari.shinyapps.io/shi https://smari.shinyapps.io/shi